ReCor Medical focuses on treating hypertension, a condition that affects over 1 billion people globally. The company has created the Paradise System, which utilizes non-focused ultrasound technology to perform renal denervation, a procedure that targets kidney nerves to help lower blood pressure. This system is particularly beneficial for patients who do not respond well to standard blood pressure medications. ReCor Medical is dedicated to clinical research and development to ensure the safety and effectiveness of its technology, and it generates revenue through the sale of its medical devices and partnerships with healthcare providers. The company is also involved in significant clinical trials, such as the RADIANCE Global Program, aimed at demonstrating the benefits of renal denervation for hypertension treatment. ReCor Medical's goal is to provide a new treatment option for high blood pressure, addressing a major global health issue.

Sofinnova Partners

Otsuka Holdings

Otsuka Pharmaceutical

Healthcare

ReCor Medical

FRANKFURT, GERMANY and PALO ALTO, Calif. , May 17, 2024 /PRNewswire/ -- Hypertension, or high blood pressure, affects one in three Europeans over the age of 30 and more than one billion people worldwide. Hypertension is known as the "silent killer" because many people do not know they have it and, over time, it can lead to serious health issues. Hypertension is the number one contributor to the burden of human disease globally, has been associated with a five-year reduction in life expectancy and is a major risk factor for heart disease, stroke, heart attacks and other serious health problems.Bloodpressure Measurement is important with HypertensionMay 17 is World Hypertension Day, a global initiative to highlight the importance of monitoring blood pressure and provide education about this devastating chronic disease. Recor Medical – the pioneer of the Paradise™ Ultrasound Renal Denervation (uRDN) System, a recently FDA-approved medical device-based procedure to treat hypertension – is joining the fight by promoting awareness and encouraging continued innovation and equitable access to early intervention and sustainable solutions for patients suffering from this chronic disease.According to a report from the World Health Organization, the number of adults with hypertension doubled between 1990 and 2019 from 650 million to 1.3 billion. The report also states that only 54 percent of adults with hypertension are diagnosed and only 42 percent receive treatment

Recor Medical Champions Global Action On World Hypertension Day: Early Intervention And Continued Innovation Crucial In Tackling This Silent Killer Impacting Billions Worldwide

FRANCFORT, ALLEMAGNE and PALO ALTO, Calif., 17 mai 2024 /PRNewswire/ -- L'hypertension artérielle, ou HTA, touche un Européen sur trois de plus de 30 ans et plus d'un milliard de personnes dans le monde. L'hypertension est appelée le "tueur silencieux" parce que de nombreuses personnes ne savent pas qu'elles en souffrent et qu'elle peut entraîner de graves problèmes de santé au fil du temps. L'hypertension est le premier facteur contribuant à la charge de morbidité mondiale et a été associée à une réduction de cinq ans de l'espérance de vie. Elle constitue un facteur de risque majeur pour les maladies cardiaques, les accidents vasculaires cérébraux, les crises cardiaques et d'autres problèmes de santé graves.Bloodpressure Measurement is important with HypertensionLe 17 mai est la Journée mondiale de l'hypertension, une action mondiale visant à souligner l'importance du contrôle de la tension artérielle et à sensibiliser à cette maladie chronique aux conséquences graves. Recor Medical - le pionnier du système Paradise™ Ultrasound Renal Denervation (uRDN), une technique médicale récemment approuvée par la FDA pour le traitement de l'hypertension artérielle - participe à cet appel en sensibilisant les gens à cette maladie et en encourageant davantage d'innovations et un accès équitable à une intervention précoce et à des solutions durables pour les patients qui souffrent de cette maladie chronique.Selon un rapport de l'Organisation mondiale de la santé, le nombre d'adultes souffrant d'hypertension a doublé entre 1990 et 2019, passant de 650 millions à 1,3 milliard. Le rapport indique également que seuls 54 % des adultes souffrant d'hypertension sont diagnostiqués et que seuls 42 % reçoivent un traitement

Recor Medical Soutient Des Actions Mondiales À L'Occasion De La Journée Mondiale De L'Hypertension : L'Intervention Précoce Et L'Innovation Continue Sont Les Clés De La Lutte Contre Ce Tueur Silencieux Qui Affecte Des Milliards De Personnes Dans Le Monde

FRANKFURT, GERMANY and PALO ALTO, Calif., 17. Mai 2024 /PRNewswire/ -- Bluthochdruck, auch Hypertonie genannt, betrifft einen von drei Europäern über 30 Jahre und mehr als eine Milliarde Menschen weltweit. Er wird auch als "stiller Killer" bezeichnet, weil viele Menschen nicht wissen, dass sie daran leiden, und er im Laufe der Zeit zu ernsthaften gesundheitlichen Problemen führen kann. Bluthochdruck ist weltweit der größte Verursacher von Krankheiten und wird mit einer um fünf Jahre verringerten Lebenserwartung in Verbindung gebracht. Er ist ein wichtiger Risikofaktor für Herzkrankheiten, Schlaganfälle, Herzinfarkte und andere schwerwiegende Gesundheitsprobleme.Bloodpressure Measurement is important with HypertensionDer 17. Mai ist der Welt-Hypertonie-Tag, eine weltweite Aktion, die auf die Wichtigkeit der Blutdruckkontrolle hinweist und über diese folgenschwere chronische Krankheit aufklärt

Recor Medical Unterstützt Weltweite Aktionen Zum Welt-Hypertonie-Tag: Frühzeitige Intervention Und Kontinuierliche Innovation Sind Der Schlüssel Zur Bekämpfung Des Stillen Killers, Von Dem Milliarden Menschen Weltweit Betroffen Sind

Recor Medical introduces Paradise uRDN system in US.

Recor Medical introduces Paradise uRDN system in US

Recor has been developing the Paradise renal denervation system for the treatment of hypertension since 2009.

FDA Approves Renal Denervation for High Blood Pressure

Recor Medical and Otsuka Medical Devices announce first fda-approved Renal Denervation system for the treatment of hypertension - Recor Medical.

Recor Medical and Otsuka Medical Devices Announce First FDA-Approved Renal Denervation System for the Treatment of Hypertension - Recor Medical

Ms. Serame joins Kyverna Therapeutics from ReCor Medical, where she served as senior director of HR.

Frederickson Partners Recruits HR Leader for Kyverna Therapeutics

ReCor Medical, part of Otsuka Holdings Co, appears to have bypassed Medtronic in the race to launch the first renal denervation (RDN) system in the US.

Cardio Catch-Up: Advisory Panel Gives Recor Momentum Toward US Launch Of RDN System

Lara Barghout is joining ReCor Medical from Siemens Healthineers, where she spent four years as senior vice president of the North American division of its advanced therapies segment.

ReCor Medical taps Siemens Healthineers alum as CEO

PALO ALTO, Calif.--(BUSINESS WIRE)-- ReCor Medical Inc. (“ReCor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”) today announced the appointment of Lara Barghout as President and Chief Executive Officer of ReCor. Ms. Barghout will lead the ReCor business strategy and organization in an exciting new direction: the global commercialization of ReCor’s Paradise™ Ultrasound Renal Denervation (“uRDN”) System for the treatment of hypertension.Ms. Barghout brings more than 20 years of experience leading global businesses in the medical device industry

Recor Medical Names Lara Barghout President And Chief Executive Officer | Biospace

Develops ultrasound technology for hypertension treatment

ReCor Medical

Develops ultrasound technology for hypertension treatment

ReCor Medical

Develops ultrasound technology for hypertension treatment

About

Simplify's Take

What believers are saying

What critics are saying

What makes ReCor Medical unique

Recently Posted Jobs

There are no jobs for ReCor Medical right now.